#320 – AMA 64: New insights on GLP-1 agonists (Ozempic, Wegovy, Mounjaro) - efficacy, benefits, risks, and considerations in the rapidly evolving weight-loss drug landscape
This AMA episode with Peter Attia, MD, and co-host Nick Stenson, delves into GLP-1 agonists like Ozempic and Mounjaro. They discuss new data on long-term efficacy, side effects, discontinuation effects, body composition, resistance training, compounding pharmacies, and promising new drugs.
Deep Dive Analysis
5 Topic Outline
Introduction to GLP-1 Agonists and Evolving Knowledge
Historical Context and Evolution of GLP-1 Agonists
Core Mechanisms of GLP-1 Agonist Action
Overview of New Data and Open Questions on GLP-1 Agonists
Long-term Safety and Efficacy of GLP-1 Agonists
4 Key Concepts
GLP-1 (Glucagon-like peptide 1)
A hormone mimicked by GLP-1 agonist drugs, which stimulates insulin release and reduces glucagon secretion from the pancreas, thereby lowering blood sugar. It also reduces gastric emptying, stimulates pro-satiety circuits in the brain, increases glucose uptake and lipolysis in fat tissue, and increases glucose oxidation in muscle.
Semaglutide
A GLP-1 receptor agonist drug, initially known by the brand name Ozempic for type 2 diabetes, and later rebranded as Wegovy for the obesity indication. It was one of the first highly effective GLP-1 agonists for weight loss.
Tirzepatide
A dual GLP-1 and GIP receptor agonist, known by the brand name Mounjaro for diabetes and Zepbound for obesity. This drug is considered slightly more effective than semaglutide due to its action on two different hormone receptors.
Retatrutide
A promising new triple receptor agonist drug that is currently in Phase 3 trials. It targets GLP-1, GIP, and glucagon receptors, suggesting a potentially broader impact on metabolic health and weight loss.
3 Questions Answered
These drugs mimic the GLP-1 hormone, stimulating insulin release and reducing glucagon from the pancreas to lower blood sugar. They also slow gastric emptying, reduce hepatic glucose production, stimulate satiety circuits in the brain, and affect glucose uptake and lipolysis in fat tissue, as well as glucose oxidation in muscle.
There is now more safety data, longer-term efficacy insights, a better understanding of weight loss mechanisms, data on weight regain post-discontinuation, and information on body composition changes and the role of exercise. Additionally, new drugs like retatrutide are in development, and the role of compounding pharmacies is being discussed.
Semaglutide is a GLP-1 receptor agonist, while tirzepatide is a dual GLP-1 and GIP receptor agonist, making tirzepatide a slightly different and potentially more effective drug due to its action on two different hormone pathways.
3 Actionable Insights
1. Seek Professional Medical Advice
Do not use podcast content as a substitute for professional medical advice; always consult healthcare professionals for any medical conditions and do not delay in obtaining medical advice.
2. Exercise Caution with Compounding Pharmacies
When considering GLP-1 drugs from compounding pharmacies, be aware that ’they’re not all created equal’ and exercise caution, as there’s a ‘buyer beware’ aspect to their use.
3. Consult Previous GLP-1 AMAs
For a deep dive into the physiology of how GLP-1 drugs work, refer to previous AMA episodes, specifically AMA 29, where the topic was covered in detail.
2 Key Quotes
If there's one thing that I get a kick out of, it's I'm scrolling on Instagram and I see a video of me talking about some aglutide from three or four years ago. And I frankly don't even necessarily agree with what I was saying at the time. And that's just the nature of how things work.
Peter Attia
It's as much nicer as it is when you have to stop having a weekly root canal.
Peter Attia